F-RESCA-RCCB6

PreclinicalSmall molecule

RRenJi Hospital

F-RESCA-RCCB6 is one of 23 small molecule programs targeting Imaging. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImagingRecruiting

ImagingPreclinical

Recruiting

Competition

Competitive Landscape

34 competitors in Imaging

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

1 2

Ritalin

Novartis

Approved

1 3

Obicetrapib

NNewAmsterdam Pharma

Phase 3

1 4

F-Arag

CCellSight Technologies, Inc.

Phase 2

2 5

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 6

PET Scan With VAT

SStony Brook University

Phase 3

1 7

XTR006

SSinotau Pharmaceutical Group

Phase 3

2 8

Ga-FAPI-46

UUniversität Münster

Phase 2

1 9

Ethanol

Roche

Preclinical

1 10

Ga-HA-DOTATATE

UUniversity of Alberta

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Imaging

NCT06852638

Clinical

Trials by Indication[1]

Imaging1 trial

CD70-targeted immunoPET Imaging of Malignant Cancers

Recruiting·RRenJi Hospital·N/A·NCT06852638·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for F-RESCA-RCCB6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — F-RESCA-RCCB6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for F-RESCA-RCCB6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RenJi Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRenJi Hospital

F-RESCA-RCCB6

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Imaging1 trial

References

Drug Info

Quick Facts

Related News